| Orexigen Therapeutics | $90 Million | Sole Manager | Unit Offering | December 2011 |
| MELA Sciences, Inc. | $16 Million | Sole Bookrunner | Registered Direct Offering | December 2011 |
| Puma Biotechnology | $60 Million | Exclusive Advisor & Lead Placement Agent | Private Placement | November 2011 |
| Zogenix | $61 Million | Joint Bookrunner | Follow-On Offering | September 2011 |
| Kythera Biopharmaceuticals | $37 Million | Sole Placement Agent | Private Placement | September 2011 |
| InterMune | $265 Million | Co-Manager | Follow-On / Convertible Senior Notes | September 2011 |
| Endocyte | $82 Million | Joint Bookrunner | Follow-On Offering | July 2011 |
| NeurogesX | $20 Million | Sole Placement Agent | Private Placement | July 2011 |
| Ventrus Biosciences | $52 Million | Joint Bookrunner | Re-IPO | July 2011 |
| Vanguard Health Systems | $518 Million | Co-Manager | Initial Public Offering | June 2011 |
| Zogenix | $32 Million | Exclusive Advisor | Structured Royalty Financing | June 2011 |
| Nationwide Better Health | Not Disclosed | Exclusive Advisor | Productivity Solutions Assets Sale | June 2011 |
| CynoSure | $25 Million | Exclusive Advisor | Acquisition of Aesthetic Business of HOYA ConBio | June 2011 |
| ArthroCare Corporation | Not Disclosed | Exclusive Financial Advisor | Sale of Parallax Assets | June 2011 |
| Anthera Pharmaceuticals | $58 Million | Joint Bookrunner | Follow-On Offering | June 2011 |
| Achillion Pharmaceuticals | $65 Million | Joint Bookrunner | Follow-On Offering | June 2011 |
| Radius Health | $66 Million | Sole Agent | Private Placement | May 2011 |
| NPS Pharmaceuticals | $114 Million | Joint Bookrunner | Follow-On Offering | April 2011 |
| HCA | $4.4 Billion | Co-Manager | (IPO) Initial Public Offering | March 2011 |
| Gilead | $1.0 Billion | Co-Manager | Senior Unsecured Notes | March 2011 |
| Fluidigm | $86 Million | Co-Manager | (IPO) Initial Public Offering | February 2011 |
| Endocyte | $86 Million | Joint Bookrunner | (IPO) Initial Public Offering | February 2011 |
| Seattle Genetics | $178 Million | Co-Lead Manager | Follow-On Offering | February 2011 |
| Pharmasset | $176 Million | Co-Manager | Follow-On Offering | January 2011 |
| Corcept Therapeutics | $45 Million | Joint Bookrunner | Follow-On Offering | January 2011 |
| ArQule | $50 Million | Joint Bookrunner | Follow-On Offering | January 2011 |
| Amarin | $105 Million | Joint Bookrunner | Follow-On Offering | January 2011 |
| Zogenix | $58 Million | Joint Bookrunner | (IPO) Initial Public Offering | November 2010 |
| Cadence Pharmaceuticals | $100 Million | Co-Lead Manager | Follow-On Offering | November 2010 |
| Aegerion Pharmaceuticals | $55 Million | Joint Bookrunner | (IPO) Initial Public Offering | October 2010 |
| Philips | Not Disclosed | Exclusive Financial Advisor | Acquisition of Discus | October 2010 |
| NuPathe | $50 Million | Joint Bookrunner | (IPO) Initial Public Offering | August 2010 |
| Gilead | $2.5 Billion | Advisor & Co-Manager | Convertible Senior Notes | July 2010 |
| Illumina | $105 Million | Exclusive Financial Advisor | Acquisition of Helixis | July 2010 |
| Sentinelle Medical | $85 Million | Exclusive Financial Advisor | Sale to Hologic | July 2010 |
| Somanetics | $329 Million | Exclusive Financial Advisor | Sale to Covidien | June 2010 |
| Pharmacyclics | $52 Million | Financial Advisor | Registered Direct | June 2010 |
| Theravance | $99 Million | Joint Bookrunner | Follow-On Offering | March 2010 |
| Aveo Pharmaceuticals | $90 Million | Co-Lead Manager | (IPO) Initial Public Offering | March 2010 |
| Amicus Therapeutics | $19 Million | Sole Placement Agent | Registered Direct | February 2010 |
| Chelsea Therapeutics | $18 Million | Lead Placement Agent | Registered Direct | February 2010 |
| Quidel Corporation | $130 Million | Financial Advisor | Acquisition of Diagnostic Hybrids | January 2010 |
| Pharmasset | $34 Million | Sole Bookrunner | Follow-On Offering | January 2010 |
| ZymoGenetics | $97 Million | Sole Bookrunner | Follow-On Offering | January 2010 |
| Biogen Idec | $493 Million | Financial Advisor | Unsolicited Tender Offer for Facet Bioech | December 2009 |
| Dendreon | $427 Million | Co-Manager | Follow-On Offering | December 2009 |
| Addrenex Pharmaceuticals | $35 Million | Financial Advisor | Sale to Sciele Pharma | November 2009 |
| AGA Medical | $199 Million | Joint Bookrunner | (IPO) Initial Public Offering | October 2009 |
| Allos Therapeutics | $99 Million | Co-Lead Manager | Follow-On Offering | October 2009 |
| Prodesse | $85 Million | Financial Advisor | Sale to Gen-Probe | October 2009 |
| Momenta | $50 Million | Sole Bookrunner | Follow-On Offering | September 2009 |
| Calypso Medical | $50 Million | Sole Agent | Private Placement | September 2009 |
| Peplin | $288 Million | Financial Advisor | Sale to LEO Pharma | September 2009 |
| Syneron | $68 Million | Sole Advisor | Merger with Candela | September 2009 |
| MAKO Surgical Corp. | $58 Million | Co-Lead Manager | Follow-On Offering | August 2009 |
| MAP Pharmaceuticals | $34 million | Co-Lead Manager | Follow-on Offering | August 2009 |
| Idenix Pharmaceuticals | $23 million | Sole Bookrunner | Registered Direct | August 2009 |
| Orexigen | $86 Million | Sole Bookrunner | Follow-On Offering | July 2009 |
| Pharmasset | $45.5 million | Sole Placement Agent | Registered Direct | January 2009 |
| Sapphire Therapeutics | $130 Million | Exclusive Financial Advisor | Sale to Helsinn | January 2009 |
| Helicos BioSciences | $19 million | Sole Agent | PIPE | December 2008 |
| Momenta Pharmaceuticals | $25 million | Sole Placement Agent | Registered Direct | December 2008 |
| United Therapeutics | $150 million | Exclusive Financial Advisor | License Tadalafil from Lilly | December 2008 |
| VisiGen | $75 million | Exclusive Financial Advisor | Sale to Invitrogen Corp. | September 2008 |
| Cellzome | N/A | Exclusive Financial Advisor | License kinase technology to GlaxoSmithKline | September 2008 |
| Cardionet | $132 million | Co-Lead Manager | Follow-on Offering | July 2008 |
| Jazz Pharmaceuticals | $26 million | Co-Agent | Registered Direct | July 2008 |
| Pharmasset | $26 million | Co-Agent | Registered Direct | July 2008 |
| BG Medicine | $40 million | Sole Agent | Private Placement | July 2008 |
| Light Sciences Oncology | $40 million | Sole Agent | Private Placement | July 2008 |
| Sequenom | $98 million | Co-Manager | Follow-on Offering | June 2008 |
| Luminex | $80 million | Co-Manager | Follow-on Offering | June 2008 |
| Javelin | $28 million | Lead Agent | Registered Direct | May 2008 |
| Neurogen | $30 million | Co-Agent | Exchangeable Preferred Stock | April 2008 |
| Cardionet | $81 Million | Co-Manager | IPO | March 2008 |
| superDimension | $22 million | Sole Agent | Private Placement | February 2008 |
| Biodel | $59 Million | Co-Manager | Follow-on Offering | February 2008 |
| Orexigen | $77 Million | Co-Lead Manager | Follow-on Offering | January 2008 |
| Cougar Biotechnology | $87 Million | Lead Agent | PIPE | December 2007 |
| Revance Therapeutics | $43 million | Sole Agent | Private Placement | December 2007 |
| Hologic | $1.7 billion | Co-Manager | Convertible Debt | December 2007 |
| Inverness Medical Innovations | $849 million | Co-Manager | Follow-on Offering | November 2007 |
| Enteromedics | $44 million | Co-Manager | IPO | November 2007 |
| Decision Biomarkers | Not Disclosed | Sole Placement Agent | Private Placement | November 2007 |
| ARYx Therapeutics | $50 million | Co-Manager | IPO | November 2007 |
| Insulet | $131 million | Co-Manager | Follow-on Offering | November 2007 |
| Chelsea Therapeutics | $49 million | Lead Agent | Registered Direct | November 2007 |
| Nanosphere | $113 million | Co-Manager | IPO | October 2007 |
| Sequenom | $30 million | Co-Agent | PIPE | October 2007 |
| Targanta Therapeutics | $58 million | Co-Manager | IPO | October 2007 |
| Sucampo Pharmaceuticals | $43 million | Co-Manager | IPO | August 2007 |
| Hana Bioscienses | $50 million | Exclusive Financial Advisor | Licensing Agreement | August 2007 |
| Sangamo | $30 million | Co-Agent | Registered Direct | June 2007 |
| Transition Therapeutics | $24 million | Financial Advisors | PIPE | June 2007 |
| Light Sciences Oncology | $30 million | Placement Agent | Private Placement | June 2007 |
| Alsius | $85 million | Exclusive Financial Advisor | Sale to Ithaka Acquisition Corp. | June 2007 |
| ArQule | $54 million | Co-Manager | Follow-on Offering | June 2007 |
| Helicos | $49 million | Co-Manager | IPO | May 2007 |
| Insulet | $116 million | Co-Manager | IPO | May 2007 |
| Javelin | $43 million | Co-Manager | IPO | May 2007 |
| Biodel | $86 million | Co-Manager | IPO | May 2007 |
| Cougar Biotechnology | $50 million | Sole Agent | PIPE | May 2007 |
| Orexigen | $97 million | Co-Manager | IPO | April 2007 |
| Poniard | $75 million | Co-Manager | Follow-on Offering | April 2007 |
| Altus Pharmaceuticals | $96 million | Co-Manager | Follow-on Offering | April 2007 |
| Light Sciences Oncology | $15 million | Sole Placement Agency | Private Placement | March 2007 |
| TransMedics | $25 million | Sole Agent | Private Placement | March 2007 |
| Chelsea Therapeutics | $13 million | Sole Placement Agent | PIPE | March 2007 |
| TM Bioscience | $70 million | Exclusive Financial Advisor | Sale to Luminex | Febuary 2007 |
| Kosan | $46 million | Co-Agent | Registered Direct | Febuary 2007 |
| Ception | $63 million | Sole Placement Agent | Private Placement | January 2007 |
| Inverness Medical Innovations | $274 million | Co-Manager | Follow-on Offering | January 2007 |
| ISIS Pharmaceuticals | $125 million | Co-Agent | Convertible Debt | January 2007 |
| Cardiome Pharma | $97 million | Co-Manager | Follow-on Offering | January 2007 |
| Neurogen | $40 Million | Co-Agent | Registered Direct | December 2006 |
| Arena | $175 Million | Co-Manager | Follow-on Offering | December 2006 |
| MannKind | $400 Million | Co-Manager | Follow-on Offering | December 2006 |
| Medivation | $36 Million | Co-Agent | Registered Direct | December 2006 |
| Hansen Medical | $86 Million | Co-Manager | IPO | November 2006 |
| CollaGenex | $45 Million | Financial Advisor | Registered Direct | November 2006 |
| Celgene | $1 Billion | Co-Manager | Follow-on Offering | November 2006 |
| Inverness Medical Innovations | $151 Million | Co-Agent | PIPE | August 2006 |
| Osiris Therapeutics | $39 Million | Co-Manager | IPO | August 2006 |
| Biodel | $21 Million | Placement Agent | Private Placement | July 2006 |
| Indevus Pharmaceuticals | $35 Million | Co-Manager | Follow-on Offering | June 2006 |
| BioProcessors | $18 Million | Sole Placement Agent | Private Placement | June 2006 |
| Sima Therapeutics | $51 Million | Co-Manager | Follow-on Offering | May 2006 |
| Northstar Neuroscience | $122 Million | Co-Manager | IPO | May 2006 |
